Atlas Trials

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

Clinical trial NCT02846623 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02846623
Sponsor
M.D. Anderson Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Lymphocytic LeukemiaRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic LeukemiaRichter SyndromeSmall Lymphocytic Lymphoma
Start date
2017-01-31
Primary completion
2027-02-28
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.